Eye Drops Recalls Expose Pharma Supply Chain Gamble: Cheaper in India, Pricier in America – Is the “Made in USA” Label a Sham?

In the latest blow to consumer trust, over 3.1 million bottles of store-brand eye drops sold at Walgreens, CVS, Rite Aid, Kroger and other major retailers were recalled this week over “lack of assurance of sterility.” The voluntary action by California-based K.C. Pharmaceuticals follows a pattern of similar crises stretching back to 2023, when Indian manufacturers like Kilitch Healthcare and Global Pharma Healthcare triggered nationwide recalls after FDA inspections uncovered barefoot workers, cracked floors, and bacterial contamination in facilities producing millions of units for the U.S. market.

These weren’t isolated incidents. Artificial tears linked to Indian plants caused dozens of infections, vision loss, and deaths in 2023. Yet the flow of low-cost generics continues. Why? Overseas production slashes expenses dramatically. Labor, facilities, and laxer oversight in India allow companies to manufacture at a fraction of U.S. costs, then ship products to American shelves where they retail for premium prices under familiar store labels.

Compounding the outrage: many bottles carry labels like “Made in USA with Global Materials.” The Federal Trade Commission permits the phrasing if final assembly occurs stateside, but critics call it deceptive marketing. Consumers scanning shelves assume American quality and safety standards. In reality, the heavy lifting—and the risk—often happens halfway around the world.

Big eye-care giants and their contract partners pocket the difference. Lower production costs boost margins while U.S. consumers pay more for what amounts to imported risk. Regulators react with recalls after harm occurs, but prevention lags. The FDA’s foreign inspections remain stretched thin, and the OTC drug market rewards volume over vigilance.

Is this smart globalization or a profit-driven shell game that puts American eyes at risk? With millions of bottles yanked and patients still suffering, it’s a question worth asking—before the next recall hits. Consumers should check lot numbers, consider single-use drops, and demand greater transparency in where their medicine truly comes from.